产品名称
盐酸奥昔布宁, ≥98% (TLC), powder
质量水平
方案
≥98% (TLC)
表单
powder
颜色
white
溶解性
H2O: 50 mg/mL
创始人
Johnson & Johnson
SMILES字符串
Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2
InChI
1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
InChI key
SWIJYDAEGSIQPZ-UHFFFAOYSA-N
基因信息
human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)
正在寻找类似产品? 访问 产品对比指南
相关类别
生化/生理作用
毒蕈碱型乙酰胆碱受体拮抗剂。
毒蕈碱型乙酰胆碱受体拮抗剂;可能通过下调生长促进基因,抑制膀胱平滑肌细胞的增殖。
特点和优势
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
此项目有
Adding to the evidence base: application drying time for oxybutynin chloride topical gel.
Cynthia M Sublett
Urologic nursing, 32(5), 270-271 (2013-03-12)
K-S Lee et al.
International journal of clinical practice, 66(7), 663-670 (2012-06-16)
Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients.
Lorne E Aaron et al.
Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)
Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for
Toshiki Hatanaka et al.
Naunyn-Schmiedeberg's archives of pharmacology, 386(1), 71-78 (2012-12-12)
Mirabegron, a selective β(3)-adrenoceptor agonist, facilitates urine storage function by exerting a relaxing effect on bladder smooth muscle. Here, we investigated the effect of mirabegron on bladder function during the storage phase. We assessed the effect of mirabegron on the
Daniele Zama et al.
Pediatric transplantation, 17(1), 86-91 (2012-12-13)
HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持